NeuroGeneces

NeuroGeneces is a Santa Fe, New Mexico health technology company working at the intersection of sleep science and neuroscience. Its NeuroInsight assessment is designed to identify atypical brain decline up to two decades before symptoms appear, with the aim of prompting behavioral and lifestyle changes early enough to be effective. The company frames current detection methods as identifying cognitive problems too late for meaningful intervention.

The product line includes a sleep headband worn by patients that also functions as a cardiac monitor. The device collects more than 400 neuro biomarkers during sleep and estimates a patient's brain age. A resulting report identifies modifiable factors that would have the greatest impact on brain age and is provided to the patient's physician. Company leadership describes the approach as measuring the brain's electrical circuitry, where changes are said to occur before cognitive or derivative symptoms emerge, giving physicians an objective measure of brain function. Trials of the assessment are underway. The company is classified in the wellness and fitness services sector, and third-party data lists its web presence as built on Squarespace with Google Workspace for collaboration.

Founding story

CEO and co-founder Karen Crow has said her interest grew out of wanting to understand her mother's Alzheimer's disease and her son's sleep disorder, leading her to conclude there was a connection between sleep science and neuroscience, and that sleep offers insight into how the brain is functioning. She founded the company in 2021 with neuropsychiatrist Dr. Jason Worchel.

Business model

NeuroGeneces sells brain-health assessment products built around a wearable sleep headband and an accompanying report. The company has been working with concierge primary care physicians to distribute its products, with the resulting report delivered to the patient's physician as an objective measure of brain function.

Traction

As of early 2025 the company reported product validation and traction in its pitch, trials of the NeuroInsight assessment underway, partnerships with concierge primary care physicians, and a planned 2025 product release. A third-party business database estimated roughly 16 employees and annual revenue in the $1M-$10M range as of August 2026.

Latest developments

In February 2025 the company won the Ski Lift Pitch competition at Taos Ski Valley, using the $10,000 prize for patent fees, and said its products would be released later in 2025 through concierge primary care physician partners while trials were ongoing.